Addex smoking cessation drug misses endpoint

ADX10061--Addex Pharmaceuticals' smoking cessation drug--did not meet the primary efficacy endpoint in a Phase IIa. The primary endpoint was to assess whether the drug increased the number of patients with four weeks continuous smoking abstinence starting from the beginning of week four of treatment. There was no difference between patients treated with ADX10061 and placebo. Addex has abandoned development of the drug.

Earlier this year Addex launched a successful IPO; the company's stock took a hit on the trial data news. Addex is also developing therapies for gastroesophageal reflux disease and migraine.

- see this release from Addex

Related Articles:
Addex pockets $111M in successful IPO. Report
Scientists identify path to addiction drug therapy. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.